Table 2 Association between death and clinical characteristics (significant level α = 0.05)
Variables | No. of deaths (%) | OR (95%CI) | P value |
|---|---|---|---|
Age, years < 65 | 2,785 (27.5) | Reference (OR = 1.00) | |
≥ 65 | 5,008 (28.9) | 1.07 (1.02–1.17) | 0.011 |
Gender | |||
Male | 6,837 (30.9) | Reference (OR = 1.00) | |
Female | 2,793 (24.9) | 0.74 (0.70–0.78) | < 0.001 |
Cancer subtype | |||
NSCLC | 7,056 (27.2) | Reference (OR = 1.00) | |
SCLC | 947 (28.9) | 1.09 (1.01–1.18) | 0.036 |
Type of inhibitors | |||
PD-1 inhibitor | 7,930 (30.7) | Reference (OR = 1.00) | |
PD-L1 inhibitor | 2,592 (24.5) | 0.73 (0.69–0.77) | < 0.001 |
Combination chemotherapy | |||
No | 8,904 (31.3) | Reference (OR = 1.00) | |
Yes | 1,618 (20.4) | 0.57 (0.53–0.60) | < 0.001 |
Per week delay in onset of the first ADE | 0.990 (0.990–0.994) | < 0.001 | |
Per ADE increase in number | 1.01 (1.00-1.02) | 0.009 | |
Per SOC involved increase in ADEs | 1.00 (0.99–1.01) | 0.475 |
